ProCE Banner Activity

Phase III IMpower132: Addition of Atezolizumab to First-line Carboplatin/Cisplatin + Pemetrexed in Stage IV Nonsquamous NSCLC

Slideset Download
Conference Coverage
In this phase III trial, patients in the atezolizumab plus platinum/pemetrexed arm showed significantly prolonged PFS vs platinum/pemetrexed in the overall population and across subgroups.

Released: September 28, 2018

Expiration: September 27, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology